Zacks Research Issues Pessimistic Forecast for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Zacks Research dropped their Q4 2025 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a research report issued to clients and investors on Wednesday, March 5th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.66 for the quarter, down from their previous estimate of $0.75. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q2 2026 earnings at $0.61 EPS, Q3 2026 earnings at $0.77 EPS, Q4 2026 earnings at $0.68 EPS and FY2027 earnings at $2.73 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%.

A number of other brokerages also recently weighed in on TEVA. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Finally, Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.57.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $15.91 on Thursday. Teva Pharmaceutical Industries has a twelve month low of $12.51 and a twelve month high of $22.80. The stock has a market capitalization of $18.03 billion, a PE ratio of -10.97, a P/E/G ratio of 1.44 and a beta of 0.71. The stock has a 50-day simple moving average of $19.15 and a 200 day simple moving average of $18.42. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Oarsman Capital Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $44,000. Smithfield Trust Co lifted its position in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $50,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $60,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.